ECCO 2022 – First Efficacy and Safety Data for TREMFYA ® in Ulcerative Colitis (UC)

Dr. Axel Dignass, M.D., Ph.D.,  Head of the Department of Medicine I and Professor of Medicine and Gastroenterology at the Agaplesion Markus Hospital, Goethe University in Frankfurt  and lead study investigator  discusses findings from the Phase 2b QUASAR trial evaluating TREMFYA ® (guselkumab) in ulcerative colitis (UC). More than 60% of adults with moderately to severely active UC achieved clinical response with TREMFYA at week 12, the study’s primary endpoint.  More than 30% of patients showed endoscopic improvement with TREMFYA at the same timepoint.  These data were presented at the 17th Congress of the European Crohn’s and Colitis Organisation (ECCO) 2022 meeting.

Professor Dr. Axel Dignass is Head of the Department of Medicine I and Professor of Medicine and Gastroenterology at the Agaplesion Markus Hospital, Goethe University in Frankfurt, and Charité Medical School, Berlin, Germany. He graduated in medicine at the University of Bochum, and later on obtained his PhD from the same university. Since then he has held numerous positions, including Research Fellow at the Massachusetts General Hospital and Harvard Medical School in Boston, USA, and Fellow, Faculty Member and Lecturer at the University of Essen in Germany. Between 1998 and 2005, Professor Dignass was an Attending Physician and Professor at Charité Medical School – Campus Virchow in Berlin, Germany, as well as Director of the IBD centre at the Charité Medical School – Campus Virchow.

Axel Dignass is a member of the International Organisation for the Study of Inflammatory Bowel Diseases (IOIBD) and Honory Member of the European Crohn’s and Colitis Organisation (ECCO). He has been Education Officer and Governing Board Member of ECCO and treasurer and governing board member of the German GI society (DGVS). He is past President of United European Gastroenterology (UEG).

His research interests focus on inflammatory bowel disease (IBD), anti-inflammatory, immunosuppressive and biologic therapy in IBD, anaemia in IBD, molecular mechanisms of intestinal wound healing and cell migration, medical guidelines, and medical education.